Literature DB >> 26364836

Monitoring for Extra-Intestinal Cancers in IBD.

H Sifuentes1, S Kane2.   

Abstract

Multiple studies have demonstrated an increased risk for extra-intestinal cancers in inflammatory bowel disease (IBD) patients, mainly from treatment modalities. Prominent cancers that are related to IBD treatment include the following: lymphoproliferative disorders associated with thiopurine use, hepatosplenic T cell lymphoma primarily in younger male patients on thiopurines and anti-tumor necrosis factor (TNF) agents, non-melanoma skin cancers in patients treated with thiopurines and anti-TNF agents, and melanomas in patients who are on monotherapy with anti-TNF agents. In addition, women with IBD may have higher rates of cervical dysplasia and cervical cancer. The focus of this review is to provide a comprehensive overview on extra-intestinal cancers in IBD patients and how to monitor for these malignancies.

Entities:  

Keywords:  Cervical cancer; Cervical dysplasia; Crohn’s disease; Extra-intestinal cancers; Hepatosplenic T cell lymphoma; Inflammatory bowel disease; Lymphoma; Lymphoproliferative disorders; Melanoma; Non-Hodgkin lymphoma; Non-melanoma skin cancer; Ulcerative colitis

Mesh：

Substances：

Year:  2015        PMID： 26364836     DOI： 10.1007/s11894-015-0467-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  38 in total

Review 1.  Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.

Authors:  Jonathan Ariyaratnam; Venkataraman Subramanian
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

Review 2.  Molecular pathogenesis of cervical cancer.

Authors:  Okechukwu A Ibeanu
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

3.  Inflammatory bowel disease is not associated with an increased risk of lymphoma.

Authors:  J D Lewis; W B Bilker; C Brensinger; J J Deren; D J Vaughn; B L Strom
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

Review 4.  Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.

Authors:  Floor Pietersma; Erwan Piriou; Debbie van Baarle
Journal:  Leuk Lymphoma       Date:  2008-06

Review 5.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

6.  Lack of association between cervical dysplasia and IBD: a large case-control study.

Authors:  C W Lees; J Critchley; N Chee; T Beez; R E Gailer; A R Williams; A G Shand; I D R Arnott; J Satsangi
Journal:  Inflamm Bowel Dis       Date:  2009-11       Impact factor: 5.325

7.  Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study.

Authors:  Christine Rungoe; Jacob Simonsen; Lene Riis; Morten Frisch; Ebbe Langholz; Tine Jess
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-30       Impact factor: 11.382

Review 8.  Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Sajan Jiv Singh Nagpal; Mohammad H Murad; Siddhant Yadav; Sunanda V Kane; Darrell S Pardi; Jayant A Talwalkar; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-02       Impact factor: 11.382

Review 9.  Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?

Authors:  Jennifer L Jones; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2007-10       Impact factor: 5.325

10.  PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients.

Authors:  C A Harwood; N R Attard; P O'Donovan; P Chambers; C M Perrett; C M Proby; J M McGregor; P Karran
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640
View more
  7 in total

Review 1.  Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Authors:  Ashwin N Ananthakrishnan; Tamara Donaldson; Karen Lasch; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

2.  Myelolipoma After Infliximab Treatment for Crohn's Disease.

Authors:  Kevin Cesa; Elaine Leonard Puppa; Katayoun Eslami; Samra M Blanchard; Runa D Watkins
Journal:  ACG Case Rep J       Date:  2022-07-01

3.  Prevalence of abnormal Pap smear results in inflammatory bowel disease: a prospective study.

Authors:  Andrea Brunner; Wolfgang Kruis; Birgid Schömig-Markiefka; Julia Morgenstern; Marianne Engels; Reinhard Büttner; Dirk Michael Forner
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-03       Impact factor: 4.322

4.  Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab.

Authors:  Diana Carvalho; Pedro Russo; Carlos Bernardes; Joana Saiote; Gonçalo Ramos; Luís Mascarenhas; Nuno Borges; Jaime Ramos
Journal:  GE Port J Gastroenterol       Date:  2017-09-06

Review 5.  Health Maintenance in Inflammatory Bowel Disease.

Authors:  Fazia A Mir; Sunanda V Kane
Journal:  Curr Gastroenterol Rep       Date:  2018-04-17

6.  Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review.

Authors:  Salvatore Cozzi; Andrea Slocker Escarpa; Daniel Lorenzo Parra; Dina Najjari Jamal; Josep Maria Caminal Mitjana; Josep Maria Piulats R; Ferran Guedea Edo; Cristina Gutierrez Miguelez
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-12

7.  The Incidence Rate and Risk Factors of Malignancy in Elderly-Onset Inflammatory Bowel Disease: A Chinese Cohort Study From 1998 to 2020.

Authors:  Zheng Wang; Huimin Zhang; Hong Yang; Mengmeng Zhang; Jiaming Qian
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.